Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.

Ruotolo, G; Båvenholm, P; Brismar, K; Eféndic, S; Ericsson, C G; de Faire, U; Nilsson, J; Hamsten, A

Ruotolo, G; Båvenholm, P; Brismar, K; Eféndic, S; Ericsson, C G; de Faire, U; Nilsson, J; Hamsten, A.

Affiliation

Ruotolo G; Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Sweden.

J Am Coll Cardiol ; 35(3): 647-54, 2000 Mar 01.

Article in En | MEDLINE | ID: mdl-10716467

Subject(s)

Bezafibrate/therapeutic use; Coronary Artery Disease/blood; Hypolipidemic Agents/therapeutic use; Insulin-Like Growth Factor I/metabolism; Myocardial Infarction/blood; Adult; Biomarkers/blood; Blood Glucose/metabolism; Coronary Angiography; Coronary Artery Disease/drug therapy; Coronary Artery Disease/physiopathology; Disease Progression; Double-Blind Method; Humans; Insulin-Like Growth Factor Binding Protein 1/blood; Lipoproteins/blood; Male; Myocardial Infarction/drug therapy; Myocardial Infarction/physiopathology; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bezafibrate / Coronary Artery Disease / Insulin-Like Growth Factor I / Myocardial Infarction / Hypolipidemic Agents Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male Language: En Journal: J Am Coll Cardiol Year: 2000 Document type: Article

Search on Google

XML

PubMed Links